View Item 

Show simple item record

Topiramate attenuates exaggerated acoustic startle in an animal model of PTSD
dc.contributor.authorKhan, Samiren_US
dc.contributor.authorLiberzon, Israelen_US
dc.date.accessioned2006-09-11T17:41:19Z
dc.date.available2006-09-11T17:41:19Z
dc.date.issued2004-03en_US
dc.identifier.citationKhan, Samir; Liberzon, Israel; (2004). "Topiramate attenuates exaggerated acoustic startle in an animal model of PTSD." Psychopharmacology 172(2): 225-229. <http://hdl.handle.net/2027.42/46359>en_US
dc.identifier.issn1432-2072en_US
dc.identifier.issn0033-3158en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/46359
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14586539&dopt=citationen_US
dc.description.abstractExaggerated acoustic startle is a prominent symptom of post-traumatic stress disorder (PTSD); however, its physiological basis is not well understood, and there are few available treatments. Neurobiological research has suggested that anti-kindling agents and/or glutamate antagonists can attenuate the acoustic startle response (ASR) in animal models. The anticonvulsant topiramate is an AMPA antagonist that also demonstrates potent anti-kindling effects and may, therefore, have promise in treating trauma-enhanced ASR.en_US
dc.format.extent175551 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlagen_US
dc.subject.otherTopiramateen_US
dc.subject.otherPTSDen_US
dc.subject.otherMedicineen_US
dc.subject.otherStartleen_US
dc.subject.otherSingle Prolonged Stressen_US
dc.titleTopiramate attenuates exaggerated acoustic startle in an animal model of PTSDen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPsychiatryen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Psychiatry, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA; VA Medical Center, Ann Arbor, 2215 Fuller Road, Ann Arbor, MI 48105, USAen_US
dc.contributor.affiliationumDepartment of Psychiatry, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA; VA Medical Center, Ann Arbor, 2215 Fuller Road, Ann Arbor, MI 48105, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid14586539en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/46359/1/213_2003_Article_1634.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/s00213-003-1634-4en_US
dc.identifier.sourcePsychopharmacologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
213_2003_Article_1634.pdf
Size:
171.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.